ESG has been a hot topic amongst the investment community recently. As climate catastrophe looms closer and closer, millennials mature and demand more from corporations and other factors continue to … [Read more...] about Mutual Fund LDVAX Booked 37%+ Returns, Is It Still A Buy?
Now that we are in the heat of summer the books have closed for the first half of the year. Here in the exclusive piece for our subscribers in which our team will individually reflect on our first … [Read more...] about MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Source: MS Money Moves Overall it was a red week for biotech whereas the greater market (S&P, NASDAQ, and DOW) gained a little under +1% each. In the past 30-days the healthcare sector … [Read more...] about Biopharma Stock Watch July 8th-12
Tumor-agnostic therapy is the idea that a molecular or genetic alteration in a tumor can be targeted by a therapy, regardless of the tumors location in the body (link). This requires that the tumor be … [Read more...] about Tumor-Agnostic Therapy: LOXO…Array…Now Who?
While writing my weekly Biopharma Stock Watch article for our members, I stumbled across an exciting clinical-stage gene therapy company Krystal Biotech (Nasdaq: KRYS). Since we started following KRYS … [Read more...] about Krystal Biotech (NASDAQ: KRYS) is On Track to Bring the First “Off the Shelf” Gene Therapy to Market
It suffices to say Q2 2019 (April-June) has been a wild ride. In 1Q19 the market bounced back with a vengeance from its low-point in December 2018 when it appeared the U.S and China were on the cusp … [Read more...] about Biopharma Stock Watch July 1st-4th
Here is a brief summary of recent, yet important developments for Calithera (CALA), TG Therapeutics (TGTX) and Array Biopharma (ARRY) that may impact your investments and trades. Calithera On … [Read more...] about INVESTOR ALERT: Calithera, TG Therapeutics, and Array Biopharma
To recap, in part 1 we talked about Evolus (Nasdaq: EOLS), a relatively young company (no pun intended) entering the medical aesthetics market. Their first product Jeuveau was approved by FDA in … [Read more...] about Evolus: A Performance Beauty Company “Built to Grow Overnight”: Part 2
Sometimes the best buying opportunities are when a company is between post-FDA approval and when sales roll in. Usually this is not the case as it takes time for sales to ramp up. Its risky for sure; … [Read more...] about Evolus: A Performance Beauty Company”Built to Grow Overnight”: Part 1
Market performance last week was substantially better than the week prior. For instance, over the 5-day time-frame all the major indices and healthcare ETFs gained over +2%. The IBB (Nasdaq Bio ETF) … [Read more...] about Biopharma Stock Watch June 24th-28th